@article{fdi:010040790,
  title = {{E}fficacy of sulfadoxine-pyrimethamine, amodiaquine, and sulfadoxine-pyrimethamine-amodiaquine combination for the treatment of uncomplicated falciparum malaria in the urban and suburban areas of {B}razzaville ({C}ongo)},
  author = {{N}dounga, {M}. and {M}ayengue, {P}. {I}. and {T}ahar, {R}achida and {C}asimiro, {P}. {N}. and {M}aya, {D}. {W}. {M}. and {M}iakassissa {M}passi, {V}. and {M}alonga, {D}. {A}. and {N}sonde {N}tandou, {F}. and {M}allanda, {G}. and {R}ingwald, {P}ascal and {B}asco, {L}eonardo and {N}toumi, {F}.},
  editor = {},
  language = {{ENG}},
  abstract = {{C}ongo-{B}razzaville has recently adopted artesunate-amodiaquine as the first-line antimalarial drug to replace chloroquine. {B}efore the implementation of this new strategy, we conducted several clinical studies to assess the therapeutic efficacy of former, classical first-line antimalarial drugs in the city of {B}razzaville, in which reside about 30% of the {C}ongolese population. {F}rom 2003 to 2005, non-randomised trials were conducted to evaluate the efficacy of sulfadoxine-pyrimethamine ({SP}) (n = 97 patients), amodiaquine ({AQ}) (n = 62 patients), and the combination of sulfadoxine-pyrimethamine-amodiaquine (n = 54 patients) in children aged between 6 months and 5 years with uncomplicated malaria using the 2003 {WHO} guidelines during the 28-day follow-up period. {A}fter excluding new infections by {PCR}, the proportion of treatment failure on day 28 was 30.2% (95% confidence interval, 19.2-43.0%) for sulfadoxine-pyrimethamine, 34.8% (95% confidence interval, 21.4-50.2%) for amodiaquine, and 14.2% (95% confidence interval, 5.9-27.2%) for sulfadoxine-pyrimethamine + amodiaquine combination. {T}reatment with sulfadoxine-pyrimethamine was associated with an increase of gametocyte charge. {T}hese results suggest that neither sulfadoxine-pyrimethamine nor amodiaquine is efficacious as monotherapy and that their combination may not remain effective in the coming years. {B}ased on our results, the implementation of artemisinin-based combination therapy appears to be urgent in the country.},
  keywords = {drug resistance ; clinical study ; plasmodiumfalciparum ; chloroquine ; drug combinations ; {CONGO} ; {BRAZZAVILLE}},
  booktitle = {},
  journal = {{A}cta {T}ropica},
  volume = {103},
  numero = {3},
  pages = {163--171},
  ISSN = {0001-706{X}},
  year = {2007},
  DOI = {10.1016/j.actatropica.2007.06.002},
  URL = {https://www.documentation.ird.fr/hor/fdi:010040790},
}